Bayer AG (BAYN.DE) 2026: German pharma/agribusiness giant burdened by Roundup litigation (Monsanto legacy). Dividend cut to €0.11/share (2024) from €2.40/share. Current yield < 1%. Marco's view: Bayer is NOT a dividend investment currently — it is a deep-value recovery play. The litigation overhang and debt make it speculative.
Bayer Stock 2026: Turnaround or Value Trap?
Bayer faces Glyphosate litigation (~€5B reserves) and Pharma pipeline concerns. The planned split into three units (Pharma, Consumer Health, Crop) could unlock value by 2027-2028. Dividend cut to minimal level. 2026 is still a restructuring year — high risk, speculative upside if litigation settles. Not investment advice.
Bayer is the stock most people laugh at. I picked it up contrarian when it was trading below €25 due to Roundup litigation. My position of 6 shares now sits at +40.93% — €66.91 in absolute gains. And right now things get interesting: Q1 2026 delivered strong results, and this summer three catalysts could resolve — or cement — the entire Roundup risk.
Forward P/E at 9 — cheap for a pharma large-cap. Novartis, Roche, GSK trade at 12–14x. Bayer trades at a 30–40% discount to peers. But ROE of −12.5% means Bayer is structurally losing money on a last-twelve-months basis. FCF yield of 9.35% means the cash is coming in — it's just being consumed by litigation.
In 2018 Bayer acquired Monsanto for $63 billion. Three months after closing, the first Roundup verdict hits. Stock crashes from €100 to €50. Today: roughly 65,000 pending lawsuits in the US. Litigation reserves: €11.8 billion. Bayer has burned €13 billion of free cash flow on litigation over five years.
Glossary: P/E Ratio explained — when a low P/E is a bargain and when it's a value trap — especially important for cyclical commodity stocks.
Glossary: EBITDA explained — what EBITDA means for commodity and shipping stocks, and why it's used as the primary valuation metric in hard assets.
Tool: Dividend Calculator — quickly calculate annual dividend income and compare multiple stocks side by side.
On February 19, 2024, CEO Bill Anderson announced the cut everyone feared: dividend reduced to 11 cents. For three years. Savings: €2.3 billion per year. In 2018 Bayer paid €2.80 per share — a DAX dividend aristocrat. My yield-on-cost at €27.25: a laughable 0.40%.
FY2025: €3.62 billion net loss — 41.8% worse than 2024. Operating margin minus 5.6%. Three consecutive years in the red. This is no temporary dip — this is a structural crisis that the market has already largely priced in.
| Date | Event | Significance |
|---|---|---|
| 04 Jun 2026 | Settlement Opt-out | Plaintiffs must accept $7.25B settlement or keep litigating |
| Late June 2026 | SCOTUS Ruling | Does federal pesticide law preempt state lawsuits? YES = 65,000 claims gone |
| 09 Jul 2026 | Final Approval Hearing | Settlement officially approved or sent back for renegotiation |
UBS mapped five scenarios: Worst case €35 (settlement fails + SCOTUS loss). Base case €52. Best case €60. Current price ~€38 — the market is pricing roughly 50/50.
Core earnings exceeded expectations significantly. 71 vs €2.28 expected — a 19% beat. EBITDA pre-special €4.45B, up 9%. Crop Science EBITDA +17.9%, soybean seeds doubled. The negative FCF comes almost entirely from €2.0B in litigation cash-out. If Roundup is resolved this summer, those €2B per quarter disappear from the P&L.
Strong (SCOTUS YES + Settlement approved): Re-rating to €52–60. Litigation risk falls away. Dividend increase from FY2027 possible. I'd be roughly 100% up on my entry.
Solid (Settlement approved, SCOTUS NO): State lawsuits continue. Stock sideways at €35–45. Deleveraging story intact but slower. I hold.
Weak (Settlement fails + SCOTUS NO): Back to €25–30. Painful, but my entry at €27.25 limits the downside. Below €25 a second buy could make sense.
While most investors focus on Bayer's pharmaceutical pipeline and Roundup litigation, the Crop Science division (soybeans, corn, vegetable seeds, herbicides) is the real cash generator in 2026. Q1 2026 highlights:
This division would be worth €20–25B as a standalone entity (rough peer multiple comparison to Corteva's ~8× EBITDA). Embedded in Bayer at current share price, you are essentially getting the pharmaceutical and H&N businesses at very low implied multiples.
The bearish case on Bayer always comes back to debt. Current debt load:
The Roundup settlement could potentially release €8–10B of provision capital over 3–4 years. If that materialises, net debt falls to ~€22B, Debt/EBITDA ratio drops to ~1.3×, and the balance sheet returns to investment-grade quality. That is the de-leveraging thesis in a nutshell.
Bayer cut its dividend to €0.11/share in 2024 (from €2.40 historically). At the current €27–38 share price range, that is a token yield of 0.3–0.4%. The dividend cut was a capital preservation move during peak litigation uncertainty.
For a dividend resumption, three conditions need to be met: (1) Roundup global settlement confirmed, (2) Net debt trajectory clearly declining, and (3) FCF turning positive sustainably. Based on Q1 2026 progress, the earliest realistic scenario for a meaningful dividend step-up is FY2027 results (announced February 2028), with a FY2026 bridge announcement possible at the November 2026 earnings call.
This is not a 2026 dividend story. It is a 2027–2028 capital appreciation + dividend recovery story. For current income needs, there are better alternatives in hard assets (shipping, mining). Bayer deserves a small asymmetric position, not a core income holding.
Bayer's litigation discount is widely discussed, but the magnitude is worth quantifying. European pharma peers trade at 12–16× forward earnings. Bayer at 9.1× represents a 30–45% discount to sector median. Even full Roundup resolution would likely only take Bayer to 11–12× (not sector median) because the company needs multiple years of clean earnings to rebuild credibility.
| Company | Fwd P/E | Dividend Yield | ROE |
|---|---|---|---|
| Bayer (BAYZF) | 9.1× | 0.3% | -12.5% |
| Novartis (NVS) | 13.5× | 3.1% | 18.2% |
| Roche (RHHBY) | 14.8× | 3.6% | 30.1% |
| AstraZeneca (AZN) | 16.1× | 1.7% | 22.4% |
The re-rating path to fair value is not "Bayer becomes Novartis overnight." It is a 3–4 year deleveraging and credibility rebuild. Investors buying at €38 are betting on the midpoint of that journey being visible from here.
Most of the MB Capital Strategies portfolio focuses on hard assets — shipping, mining, energy, pipelines. Bayer is the one pharmaceutical position: a small, deliberate asymmetric bet that sits outside the core income strategy. The rationale for holding it alongside shipping names like TORM, FLEX LNG, and CMB.Tech is diversification of risk type: shipping dividends are cycle-sensitive (oil/freight rates), Bayer is litigation-sensitive (SCOTUS/settlement). Neither risk is correlated to the other.
At 6 shares with a total cost of €163.50, Bayer is a small position by design. The maximum loss scenario (complete Roundup failure, stock back to €20) costs approximately €45 on the position — less than one month of shipping dividend income. The asymmetric structure justifies holding it as an option, not a core holding.
Bayer is not a dividend investment — it's an asymmetric bet. Q1 2026 showed Anderson can deliver operationally. Three summer catalysts determine the rest. I hold my 6 shares and watch what SCOTUS says in late June. Adding before a directional decision isn't on my agenda.
More Stock Analysis
Understanding FCF for dividends? → Free Cash Flow Explained: Why FCF Is the Only Metric That Matters →
How safe is the dividend? → Dividend Coverage Ratio Explained — Payout Safety Metric →
Marco Bozem
All tanker stocks ranked: best tanker stocks 2026.
Investor & Analyst | Hard Assets, Dividends, Shipping | MB Capital Strategies
Marco has been analyzing commodity and dividend stocks for years, focusing on shipping, mining, and energy. All analyses are based on publicly available annual reports and his own assessment. Not investment advice.
See also: Best High-Yield Dividend Stocks 2026